Tibsovo (IVosidenib) Patent Expiration, LOE Window & CMS Spending
Tibsovo (IVosidenib) by Servier: FDA Orange Book core substance LOE 2033-08-19 (last listed 2039-06-07), 0 AB generics, $307.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Servier |
| FDA Application & Pathway | N211192 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2033-08-19 |
| Last Listed Patent or Exclusivity Date | 2039-06-07 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $307.1M |
| 2024 Medicare Part D Spend | $265.2M |
| 2024 Medicaid Spend | $41.8M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 17.4% 2-yr change) |